Answers are grounded in this paper and cite their sources.
Salinosporamide A is a β-lactone proteasome inhibitor currently in clinical trials for the treatment of multiple-myeloma. Herein we report a short synthesis of this small, highly functionalized, biologically important natural product that uses an oxidative radical cyclization as a key step and allows for the preparation of gram quantities of advanced synthetic intermediates.
No takes yet. Share an insight, caveat, or question.
Marx et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: